• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . Epidemiology and genomic features of MERS coronavirus in Africa: a systematic and meta-analysis review

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2026 Feb 3:108456.
doi: 10.1016/j.ijid.2026.108456. Online ahead of print.
Epidemiology and genomic features of MERS coronavirus in Africa: a systematic and meta-analysis review

Brian Ogoti[SUP] 1 [/SUP], Victor Riitho[SUP] 2 [/SUP], Johanna Wildemann[SUP] 3 [/SUP], Nyamai Mutono[SUP] 4 [/SUP], Marianne Mureithi[SUP] 5 [/SUP], Prof Julius Oyugi[SUP] 6 [/SUP], Jordi Rodon[SUP] 3 [/SUP], Victor M Corman[SUP] 7 [/SUP], Prof Christian Drosten[SUP] 7 [/SUP], Prof S M Thumbi[SUP] 8 [/SUP], Prof Marcel A Müller[SUP] 9 [/SUP]


Affiliations
Free article Abstract

Objective: We explored factors contributing to the low human MERS-CoV prevalence in Africa by assessing MERS-CoV epidemiological and genomic features.
Methods: We followed the PRISMA guidelines. We searched for articles on epidemiological and virological MERS-CoV characteristics in humans and camels in Africa until August 2025. We used a generalised linear mixed-effects model to calculate pooled proportions. We identified relevant polymorphisms in African MERS-CoV lineages compared with the prototypic EMC/2012 and contemporary Arabian MERS-CoV (clade B5).
Results: We included 53 articles, with 31 used in the meta-analysis. Kenya, Egypt, and Ethiopia contributed to 66.03% of all included studies. Pooled MERS-CoV RNA positivity in African dromedaries was 6.09%, with juveniles (15.29%) having a higher incidence than adults (4.51%). The pooled MERS-CoV seroprevalence was 73.67%, with adults (80.96%) higher than juveniles (36.02%). In human-focused studies, only nine PCR-confirmed MERS cases were reported, six travel-associated and three autochthonous cases, despite a pooled seroprevalence of 2.4%. Genomic analyses identified MERS-CoV clade C-specific polymorphisms in the Spike and accessory genes with putative phenotypic impact.
Conclusion: We found the highest MERS-CoV RNA positivity in young dromedaries. Elevated MERS-CoV seroprevalence in mainly asymptomatic camel-exposed humans suggests an underestimation of MERS-CoV infections in Africa. The ongoing MERS-CoV evolution emphasises the need for active genomic surveillance to monitor signatures of human adaptation.

Keywords: Africa; MERS, coronavirus; MERS-CoV; dromedary camel; epidemiology; genotype; meta-analysis; phenotype; systematic review; zoonosis.

 
Back
Top